← Patent-cliff monitor small molecule QFITLIA FITUSIRAN SODIUM
Loss of exclusivity December 2036 latest FDA-listed patent expiry
Company Genzyme → See this company's full patent-cliff portfolio Drug detail Brand name QFITLIA Active ingredient FITUSIRAN SODIUM Strength EQ 50MG BASE/0.5ML (EQ 50MG BASE/0.5ML) Dosage form SOLUTION Route SUBCUTANEOUS Modality Small molecule FDA approval March 2025 Marketing status RX
Listed patents Patent Expires Type 11091759 December 2036 use U-4165 9127274 March 2033 substance, product 9376680 March 2033 substance, product
Regulatory exclusivity Code Expires ODE-510 March 2032 ODE-511 March 2032 NCE March 2030
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.